MarketPulse

clinical-stage biopharmaceutical

17 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Acumen Pharma to Present Alzheimer's Drug Data at BofA Conference

Acumen Pharma to present at BofA Securities conference May 14 ahead of late-2026 Alzheimer's drug trial results.
ABOSmonoclonal antibodyclinical-stage biopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Acumen Pharma Eyes Alzheimer's Breakthrough as Q1 Results Loom

Acumen Pharmaceuticals to report Q1 2026 results May 12, with Phase 2 Alzheimer's drug data expected later this year.
HALOABOSclinical-stage biopharmaceuticalAlzheimer's disease
GlobeNewswire Inc.GlobeNewswire Inc.··Agomab Therapeutics Nv

Agomab Raises $208M in IPO, Extends Runway to 2029 Amid Pipeline Progress

Agomab Therapeutics raised $208M in February 2026 IPO and reported €116.5M cash, funding operations into H1 2029 while advancing two lead drug candidates.
AGMBIPOclinical-stage biopharmaceutical
BenzingaBenzinga··Prnewswire

Viking Therapeutics to Report Q1 2026 Results; Obesity Drug VK2735 in Focus

Viking Therapeutics will report Q1 2026 earnings April 29 after market close, showcasing progress on obesity and metabolic disorder treatments.
VKTXfinancial resultsPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Bolsters Executive Team Ahead of Critical Lanifibranor Phase 3 Data

Inventiva appoints three new executives to strengthen leadership before anticipated Phase 3 lanifibranor trial results expected in Q4 2026.
IVAGeneral CounselPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

IN8bio Grants Stock Options to New Employees Under Nasdaq Inducement Rules

IN8bio issued 11,800 stock options to two new employees on April 1, 2026, as hiring incentives under Nasdaq listing regulations.
INABautoimmune diseasescancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Bioversys Ag

BioVersys Bolsters NTM Pipeline via Hackensack Meridian Ansamycin Partnership

BioVersys expands NTM pipeline through exclusive ansamycin chemistry partnership with Hackensack Meridian Health, strengthening BV500 program with Shionogi.
SGIOYclinical-stage biopharmaceuticalantimicrobial resistance
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Monopar Strengthens Balance Sheet With $92M Raise, Eyes 2026 Drug Submission

Monopar reports $13.7M net loss, $140.4M cash reserves funding operations through 2027. Company plans mid-2026 NDA submission for Wilson disease treatment ALXN1840.
MNPRfinancial resultsFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Nrx Pharmaceuticals, Inc.

NRx Pharmaceuticals to Unveil 2025 Results, Update on Breakthrough Psychiatric Drug Pipeline

NRx Pharmaceuticals to report 2025 results March 24, 2026, updating on FDA-designated ketamine and PTSD programs with significant clinical potential.
NRXPNRXPWfinancial resultsclinical-stage biopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

OKYO Pharma CDO Backs Pipeline With $49K Share Purchase as Phase 2b/3 Trial Looms

OKYO Pharma's Chief Development Officer purchases 30,980 shares at $1.59, signaling confidence in urcosimod as company prepares Phase 2b/3 trial launch in H1 2026.
OKYOclinical-stage biopharmaceuticalneuropathic corneal pain
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Neumora to Unveil 2025 Results as Pipeline Advances Toward Critical Trial Readouts

Neumora Therapeutics will report 2025 financial results March 30, 2026, with major KOASTAL trial readouts anticipated in Q2 2026.
NMRAfinancial resultsclinical-stage biopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Minerva Neurosciences, Inc.

Minerva Neurosciences Posts $293M Loss But Bolsters Cash Reserves for Schizophrenia Drug Trial

Minerva Neurosciences reported $293.4M FY2025 net loss, largely from non-cash charges. The biotech secured $80M funding and plans Phase 3 roluperidone trial launch in Q2 2026.
NERVprivate placementPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Actuate Therapeutics to Unveil Cancer Pipeline Expansion at Citizens Conference

Actuate Therapeutics plans to present at the Citizens Life Sciences Conference on March 10, advancing elraglusib tablet into Phase 1/2 oncology trials launching H2 2026.
ACTUcancer therapypipeline expansion
GlobeNewswire Inc.GlobeNewswire Inc.··Na

MAIA Biotech Raises $30M in Public Offering to Fund Clinical Trials

MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/share, funding clinical trials and operations.
MAIApublic offeringcommon stock
GlobeNewswire Inc.GlobeNewswire Inc.··Na

MAIA Biotech Raises $30M via Stock Offering to Fund Clinical Trials

MAIA Biotechnology prices $30M public offering at $1.50/share to fund clinical trials. Offering closes March 4, 2026.
MAIApublic offeringcommon stock
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Bicara Therapeutics Raises $150M Through Stock and Warrant Offering

Bicara Therapeutics raises $150M through stock and warrant offering to fund lead drug candidate development, expand manufacturing, and build commercial infrastructure.
BCAXEGFRpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Strengthens Balance Sheet With $172.5M Offering; Eyes Mid-2027 Cash Runway

Inventiva raises $172.5M, strengthening balance sheet to €230.9M in liquidity. Clinical-stage biotech projects cash runway through mid-2027 to advance MASH treatment program.
IVApublic offeringclinical-stage biopharmaceutical